Trial Profile
A double-blind, placebo-controlled study of the effect of MK-0966 [rofecoxib] on blood and synovial fluid prostaglandin levels and synovial fluid MK-0966 concentrations in patients with rheumatoid arthritis (RA)
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 12 Jan 2006
Price :
$35
*
At a glance
- Drugs Rofecoxib (Primary) ; Diclofenac
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics
- 12 Jan 2006 New trial record.